Study on pathological indicator to predict response of cancer immune therapy

• Project/Area Number: 18K07036
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 49020:Human pathology-related
• Research Institution: Research Institute for Clinical Oncology Saitama Cancer Center (2021); National Cancer Center Japan (2018-2020)
• Principal Investigator: Motoi Noriko 地方独立行政法人埼玉県立病院機構埼玉県立がんセンター(臨床腫瘍研究所), 病院 病理診断科, 医長 (70292878)
• Project Period (FY): 2018-04-01 – 2022-03-31
• Project Status: Completed (Fiscal Year 2021)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 形態学的バイオマーカー / デジタル病理学 / 免疫療法 / バイオマーカー / 治療効果予測 / 予後予測 / 病理形態学 / 予後予測指標 / がん免疫環境 / デジタル画像解析 / 予後予測因子 / 肺癌 / がん免疫療法 / 病理形態学的指標

Outline of Final Research Achievements

The purpose of this study is to establish the pathological indicators necessary for optimal medical care of cancer. We investigated for pathological predictive indicators for ICI using lung cancer pathological specimens and examined their significance. (1) In lung cancer, we found that the pathomorphological index (MBM) is an index for predicting the effect of ICI. Deep learning of digital images (DNN-MBM) showed better therapeutic effect prediction performance than conventional PD-L1. (2) MBM was an index with higher predictability, independent of gene mutation, TMB, and PD-L1. (3) In NSCLC and SCLC, it was shown that the state of immune cells in the cancer microenvironment is related to the prognosis and the therapeutic effect of ICI. MBM for lung cancer has been shown to be a promising new biomarker for ICI.

Academic Significance and Societal Importance of the Research Achievements

肺癌は、個別化医療が進み分子標的治療や免疫チェックポイント阻害剤（ICI）などの薬剤が開発され、患者に大きな恩恵をもたらしているものの、治療方針の最適化のためには、がんの個性を読み解き、適した治療を選択する指標（バイオマーカー）を確立する必要がある。ICIのバイオマーカー としてはPD-L1が普及しているが、その性能は不十分で、より精度の高いバイオマーカーの探索と確立は喫緊の課題である。本研究では、従来のPD-L1よりも優れた予測性能があるバイオマーカーとして形態学的バイオマーカー（MBM）が提案できた。今後、がん医療への貢献が期待される成果である。

Research Products

• [Journal Article] Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer (2022)
  • Author(s): Shirasawa Masayuki、Yoshida Tatsuya、Imabayashi Tatsuya、Okuma Kae、Matsumoto Yuji、Masuda Ken、Shinno Yuki、Okuma Yusuke、Goto Yasushi、Horinouchi Hidehito、Tsuchida Takaaki、Yamamoto Noboru、Nakayama Yuko、Watanabe Shun-ichi、Motoi Noriko、Ohe Yuichiro
  • Journal Title: European Journal of Cancer Volume: 162 Pages: 1-10
  • DOI: 10.1016/j.ejca.2021.11.013
  • Peer Reviewed
• [Journal Article] “Real” Tumor-Spread Through Air Spaces of Lung Adenocarcinoma Presented Intrapulmonary Metastases Through Bronchiole Air Spaces: A Case Report (2022)
  • Author(s): Kaku Sawako、Motoi Noriko、Watanabe Hirokazu、Yoshida Yukihiro、Watanabe Shun-ichi、Kusumoto Masahiko
  • Journal Title: JTO Clinical and Research Reports Volume: 3 Issue: 2 Pages: 100273-100273
  • DOI: 10.1016/j.jtocrr.2021.100273
  • Peer Reviewed / Open Access
• [Journal Article] A Case of Lung Adenocarcinoma Harboring <i>EGFR</i> Exon19 Deletion/Insertion Mutation Detected by Next-Generation Sequencing (NGS), but Not by PCR (2021)
  • Author(s): Nishiyama Kazuhiro、Furuya Naoki、Tsuruoka Hajime、Azagami Shinya、Kakinuma Kazutaka、Inoue Takeo、Endou Akira、Mineshita Masamichi、Motoi Noriko
  • Journal Title: Haigan Volume: 61 Issue: 2 Pages: 143-144
  • DOI: 10.2482/haigan.61.143
  • NAID: 130008031682
  • ISSN: 0386-9628, 1348-9992
  • Year and Date: 2021-04-20
  • Peer Reviewed / Open Access
• [Journal Article] Elastin in pulmonary pathology: relevance in tumours with a lepidic or papillary appearance. A comprehensive understanding from a morphological viewpoint (2021)
  • Author(s): Thunnissen Erik、Motoi Noriko、Minami Yuko、Matsubara Daisuke、Timens Wim、Nakatani Yukio、Ishikawa Yuichi、Baez‐Navarro Ximena、Radonic Teodora、Blaauwgeers Hans、Borczuk Alain C、Noguchi Masayuki
  • Journal Title: Histopathology Volume: 80 Issue: 3 Pages: 457-467
  • DOI: 10.1111/his.14537
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab (2021)
  • Author(s): Jo Hitomi、Yoshida Tatsuya、Horinouchi Hidehito、Yagishita Shigehiro、Matsumoto Yuji、Shinno Yuki、Okuma Yusuke、Goto Yasushi、Yamamoto Noboru、Takahashi Kazuhisa、Motoi Noriko、Ohe Yuichiro
  • Journal Title: Cancer Immunology, Immunotherapy Volume: 71 Issue: 2 Pages: 387-398
  • DOI: 10.1007/s00262-021-02997-2
  • Peer Reviewed
• [Journal Article] Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non?small Cell Lung Cancer PDX Models with Driver Genetic Alterations (2021)
  • Author(s): Jo Hitomi、Yagishita Shigehiro、Hayashi Yoshiharu、Ryu Shoraku、Suzuki Mikiko、Kohsaka Shinji、Ueno Toshihide、Matsumoto Yuji、Horinouchi Hidehito、Ohe Yuichiro、Watanabe Shun-ichi、Motoi Noriko、Yatabe Yasushi、Mano Hiroyuki、Takahashi Kazuhisa、Hamada Akinobu
  • Journal Title: Molecular Cancer Therapeutics Volume: 21 Issue: 2 Pages: 359-370
  • DOI: 10.1158/1535-7163.mct-21-0371
  • Peer Reviewed / Open Access
• [Journal Article] Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors (2021)
  • Author(s): Yoh Kiyotaka、Matsumoto Shingo、Furuya Naoki、Nishino Kazumi、Miyamoto Shingo、Oizumi Satoshi、Okamoto Norio、Itani Hidetoshi、Kuyama Shoichi、Nakamura Atsushi、Nishi Koichi、Fukuda Ikue、Tsuta Koji、Hayashi Yuichiro、Motoi Noriko、Ishii Genichiro、Goto Koichi
  • Journal Title: Lung Cancer Volume: 159 Pages: 128-134
  • DOI: 10.1016/j.lungcan.2021.07.015
  • Peer Reviewed
• [Journal Article] Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma (2021)
  • Author(s): Shirasawa Masayuki、Yoshida Tatsuya、Takayanagi Daisuke、Shiraishi Kouya、Yagishita Shigehiro、Sekine Katsutoshi、Kanda Shintaro、Matsumoto Yuji、Masuda Ken、Shinno Yuki、Okuma Yusuke、Goto Yasushi、Horinouchi Hidehito、Hamada Akinobu、Kohno Takashi、Yamamoto Noboru、Watanabe Shun-ichi、Ohe Yuichiro、Motoi Noriko
  • Journal Title: Clinical Lung Cancer Volume: 22 Issue: 4 Pages: 282-291
  • DOI: 10.1016/j.cllc.2021.02.003
  • Peer Reviewed
• [Journal Article] Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC (2021)
  • Author(s): Shirasawa Masayuki、Yoshida Tatsuya、Shimoda Yukiko、Takayanagi Daisuke、Shiraishi Kouya、Kubo Takashi、Mitani Sachiyo、Matsumoto Yuji、Masuda Ken、Shinno Yuki、Okuma Yusuke、Goto Yasushi、Horinouchi Hidehito、et al. and Motoi Noriko
  • Journal Title: Journal of Thoracic Oncology Volume: 16 Issue: 12 Pages: 2078-2090
  • DOI: 10.1016/j.jtho.2021.07.027
  • Peer Reviewed
• [Journal Article] Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients (2021)
  • Author(s): SHIMODA YUKIKO、YOSHIDA TATSUYA、SHIRASAWA MASAYUKI、MIZUNO TAKAAKI、JO HITOMI、MATSUMOTO YUJI、SHINNO YUKI、OKUMA YUSUKE、GOTO YASUSHI、HORINOUCHI HIDEHITO、YAMAMOTO NOBORU、YATABE YASUSHI、OHE YUICHIRO、MOTOI NORIKO
  • Journal Title: Anticancer Research Volume: 41 Issue: 11 Pages: 5739-5747
  • DOI: 10.21873/anticanres.15390
  • Peer Reviewed / Open Access
• [Journal Article] The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC (2021)
  • Author(s): Mino-Kenudson Mari、Le Stang Nolwenn、Daigneault Jillian B.、Nicholson Andrew G.、Cooper Wendy A.、Roden Anja C.、Moreira Andre L.、Thunnissen Erik、Papotti Mauro、Pelosi Giuseppe、Motoi Noriko、et al. and Lantuejoul Sylvie
  • Journal Title: Journal of Thoracic Oncology Volume: 16 Issue: 4 Pages: 686-696
  • DOI: 10.1016/j.jtho.2020.12.026
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Influence of degree of DNA degradation in formalin-fixed and paraffin-embedded tissue samples on accuracy of genome-wide DNA methylation analysis (2021)
  • Author(s): Ueda S, Yamashita S, Watanabe S-i, Wakabayashi M, Motoi N, Noguchi M, Sekine S, Sato Y, Ushijima T.
  • Journal Title: Epigenomics Volume: － Issue: 8 Pages: 565-576
  • DOI: 10.2217/epi-2020-0431
  • Peer Reviewed
• [Journal Article] HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR-TKIs (2021)
  • Author(s): Watanabe S, Goto Y, Yasuda H, Kohno T, Motoi N, Ohe Y, Nishikawa H, Kobayashi SS, Kuwano K, Togashi Y.
  • Journal Title: Thoracic Cancer Volume: 12 Issue: 5 Pages: 631-42
  • DOI: 10.1111/1759-7714.13839
  • Peer Reviewed / Open Access
• [Journal Article] Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib (2021)
  • Author(s): Takahashi T, Umeguchi H, Tateishi A, Yoshida T, Motoi N, Ohe Y.
  • Journal Title: Lung Cancer Volume: 151 Pages: 1-4
  • DOI: 10.1016/j.lungcan.2020.11.010
  • Peer Reviewed
• [Journal Article] Pulmonary microinvasive small cell carcinoma with extensive in situ component identified after photodynamic therapy for 窶?squamous cell carcinoma in situ窶?: A case report (2021)
  • Author(s): Ota M, Nakatani Y, Nakajima T, Hiroshima K, Motoi N, Yoshino I, Ikeda J-i.
  • Journal Title: Histopathology Volume: 78 Issue: 6 Pages: 912-6
  • DOI: 10.1111/his.14308
  • Peer Reviewed
• [Journal Article] Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants (2021)
  • Author(s): Arakawa A, Ichikawa H, Kubo T, Motoi N, Kumamoto T, Nakajima M, Yonemori K, Noguchi E, Sunami K, Shiraishi K, Kakishima H, Yoshida H, Hishiki T, Kawakubo N, Kuroda T, Kiyokawa T, Yamada K, Yanaihara N, et al, and Kohno T, Ogawa C.
  • Journal Title: New England Journal of Medicine Volume: 384 Issue: 1 Pages: 42-50
  • DOI: 10.1056/nejmoa2030391
  • Peer Reviewed / Open Access
• [Journal Article] Feasibility of next-generation sequencing (Oncomine邃「 DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients (2021)
  • Author(s): Takeyasu Y, Yoshida T, Motoi N, Teishikata T, Tanaka M, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Kakishima H, Tsuchida T, Yamamoto N, Ohe Y, Yatabe Y.
  • Journal Title: Jpn J Clin Oncol Volume: 繝シ Issue: 7 Pages: 1114-1122
  • DOI: 10.1093/jjco/hyab059
  • Peer Reviewed / Open Access
• [Journal Article] Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS >/= 50%) NSCLC (2020)
  • Author(s): Takeyasu Y, Yoshida T, Shibaki R, Matsumoto Y, Goto Y, Kanda S, Horinouchi H, Yamamoto N, Motoi N, Ohe Y.
  • Journal Title: Clin Lung Cancer Volume: － Issue: 2 Pages: 127-133.e3
  • DOI: 10.1016/j.cllc.2020.10.002
  • Peer Reviewed
• [Journal Article] Impact of chemoradiotherapy (CRT) on immune-related tumor microenvironment and efficacy of anti-PD-1 therapy for recurrences after CRT in patients with unresectable locally advanced NSCLC (2020)
  • Author(s): Shirasawa M, Yoshida T, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yamamoto N, Watanabe S-i, Ohe Y, Motoi N.
  • Journal Title: European Journal of Cancer Volume: 140 Pages: 28-36
  • Peer Reviewed
• [Journal Article] Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment (2020)
  • Author(s): Shirasawa M, Yoshida T, Horinouchi H, Kitano S, Arakawa S, Matsumoto Y, Shinno Y, Okuma Y, Goto Y, Kanda S, Watanabe R, Yamamoto N, Watanabe S-i, Ohe Y, Motoi N.
  • Journal Title: British Journal of Cancer Volume: － Issue: 5 Pages: 925-932
  • DOI: 10.1038/s41416-020-01188-7
  • Peer Reviewed
• [Journal Article] CD20(+) tumor‐infiltrating immune cells and CD204(+) M2 macrophages are associated with prognosis in thymic carcinoma (2020)
  • Author(s): Sato Jun、Kitano Shigehisa、Motoi Noriko、Ino Yoshinori、Yamamoto Noboru、Watanabe Shunichi、Ohe Yuichiro、Hiraoka Nobuyoshi
  • Journal Title: Cancer Science Volume: － Issue: 6 Pages: 1921-1932
  • DOI: 10.1111/cas.14409
  • Peer Reviewed / Open Access
• [Journal Article] Long-read sequencing for non-small-cell lung cancer genomes (2020)
  • Author(s): Sakamoto Y, Xu L, Seki M, Yokoyama TT, Kasahara M, Kashima Y, Ohashi A, Shimada Y, Motoi N, Tsuchihara K, Kobayashi SS, Kohno T, Shiraishi Y, Suzuki A, Suzuki Y.
  • Journal Title: Genome Res Volume: 30 Issue: 9 Pages: 1243-57
  • DOI: 10.1101/gr.261941.120
  • Peer Reviewed / Open Access
• [Journal Article] Feasibility study of cryobiopsy for practical pathological diagnosis of primary lung cancer including immunohistochemical assessment (2020)
  • Author(s): Nishida T, Matsumoto Y, Sasada S, Tanaka M, Nakai T, Fukai R, Ohe Y, Watanabe SI, Motoi N.
  • Journal Title: Jpn J Clin Oncol Volume: 繝シ Issue: 2 Pages: 271-278
  • DOI: 10.1093/jjco/hyaa174
  • Peer Reviewed
• [Journal Article] A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee (2020)
  • Author(s): Moreira AL, Ocampo PSS, Xia Y, Zhong H, Russell PA, Minami Y, Cooper WA, Yoshida A, Bubendorf L, Papotti M, Pelosi G, Lopez-Rios F, Kunitoki K, Ferrari-Light D, Sholl LM, et al., Motoi N, Noguchi M, et al., and Nicholson AG, Mino-Kenudson M.
  • Journal Title: J Thorac Oncol Volume: 15 Issue: 10 Pages: 1599-610
  • DOI: 10.1016/j.jtho.2020.06.001
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee (2020)
  • Author(s): Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, Lopez-Rios F, Jain D, Chou TY, Motoi N, et al. and Wistuba, II, Mino-Kenudson M.
  • Journal Title: J Thorac Oncol Volume: 15 Issue: 4 Pages: 499-519
  • DOI: 10.1016/j.jtho.2019.12.107
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Clinical outcomes of pembrolizumab therapy in advanced-NSCLC patients with poor performance status (竕・3) and high PD-L1 expression (TPS 竕・50%): A case series (2020)
  • Author(s): Inaba-Higashiyama R, Yoshida T, Jo H, Shirasawa M, Motoi N, Ohe Y.
  • Journal Title: Thoracic Cancer Volume: 11 Issue: 12 Pages: 3618-21
  • DOI: 10.1111/1759-7714.13713
  • Peer Reviewed
• [Journal Article] Chaperone-mediated autophagy receptor modulates tumor growth and chemoresistance in non-small cell lung cancer (2020)
  • Author(s): Ichikawa A, Fujita Y, Hosaka Y, Kadota T, Ito A, Yagishita S, Watanabe N, Fujimoto S, Kawamoto H, Saito N, Yoshida M, Hashimoto M, Minagawa S, Hara H, Motoi N, Yamamoto Y, Ochiya T, Araya J, Kuwano K.
  • Journal Title: Cancer Sci Volume: 111 Issue: 11 Pages: 4154-65
  • DOI: 10.1111/cas.14629
  • Peer Reviewed / Open Access
• [Journal Article] RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient (2020)
  • Author(s): Arakawa S, Yoshida T, Shirasawa M, Takayanagi D, Yagishita S, Motoi N, Ohe Y.
  • Journal Title: Lung Cancer Volume: 繝シ Pages: 101-103
  • DOI: 10.1016/j.lungcan.2020.11.016
  • Peer Reviewed
• [Journal Article] Small Cell Cancer Transformation of Lung Adenocarcinoma During Durvalumab Treatment After Chemoradiotherapy (2020)
  • Author(s): Arakawa S, Yoshida T, Nakayama Y, Motoi N, Ohe Y.
  • Journal Title: J Thorac Oncol Volume: 15 Issue: 8 Pages: e145-e146
  • DOI: 10.1016/j.jtho.2019.12.117
  • Peer Reviewed
• [Journal Article] Lung cancer biomarker tests: the history and perspective in Japan (2020)
  • Author(s): Motoi N, Yatabe Y.
  • Journal Title: Translational lung cancer research Volume: － Issue: 3 Pages: 879-886
  • DOI: 10.21037/tlcr.2020.03.09
  • Peer Reviewed / Open Access
• [Journal Article] Correlation between the expression of folate receptor alpha (FRα) and clinicopathological features in patients with lung adenocarcinoma (2020)
  • Author(s): Tamura Nobumasa、Fujiwara Yutaka、Hashimoto Taiki、Shiraishi Hideaki、Kitano Shigehisa、Shimizu Toshio、Kuwano Kazuyoshi、Yamamoto Noboru、Motoi Noriko
  • Journal Title: Lung Cancer Volume: 145 Pages: 152-157
  • DOI: 10.1016/j.lungcan.2020.05.002
  • Peer Reviewed
• [Journal Article] Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab (2020)
  • Author(s): Namikawa Kenjiro、Takahashi Akira、Mori Taisuke、Tsutsumida Arata、Suzuki Shigenobu、Motoi Noriko、Jinnai Shunichi、Kage Yuta、Mizuta Haruki、Muto Yusuke、Nakano Eiji、Yamazaki Naoya
  • Journal Title: Melanoma Research Volume: 30 Issue: 1 Pages: 76-84
  • DOI: 10.1097/cmr.0000000000000617
  • Peer Reviewed
• [Journal Article] Small cell cancer transformation of lung adenocarcinoma during durvalumab treatment following chemoradiotherapy (2020)
  • Author(s): Arakawa S, Yoshida T, Nakayama Y, Motoi N, Ohe Y.
  • Journal Title: Journal of Thoracic Oncology Volume: －
  • Peer Reviewed
• [Journal Article] Malignant pleural effusion as a predictor of the efficacy of anti‐PD‐1 antibody in patients with non‐small cell lung cancer (2019)
  • Author(s): Shibaki Ryota、Murakami Shuji、Shinno Yuki、Matsumoto Yuji、Goto Yasushi、Kanda Shintaro、Horinouchi Hidehito、Fujiwara Yutaka、Motoi Noriko、Yamamoto Noboru、Ohe Yuichiro
  • Journal Title: Thoracic Cancer Volume: 10 Issue: 4 Pages: 815-822
  • DOI: 10.1111/1759-7714.13004
  • Peer Reviewed / Open Access
• [Journal Article] Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease (2019)
  • Author(s): Shibaki Ryota、Murakami Shuji、Matsumoto Yuji、Goto Yasushi、Kanda Shintaro、Horinouchi Hidehito、Fujiwara Yutaka、Yamamoto Nobuyuki、Motoi Noriko、Kusumoto Masahiko、Yamamoto Noboru、Ohe Yuichiro
  • Journal Title: Medical Oncology Volume: 36 Issue: 6
  • DOI: 10.1007/s12032-019-1274-0
  • Peer Reviewed
• [Journal Article] Cryobiopsy during flex-rigid pleuroscopy: an emerging alternative biopsy method in malignant pleural mesothelioma. A comparative study of pathology (2019)
  • Author(s): Nakai Toshiyuki、Matsumoto Yuji、Sasada Shinji、Tanaka Midori、Tsuchida Takaaki、Ohe Yuichiro、Motoi Noriko
  • Journal Title: Japanese Journal of Clinical Oncology Volume: - Issue: 6 Pages: 559-566
  • DOI: 10.1093/jjco/hyz032
  • Peer Reviewed
• [Journal Article] Successful treatment with nivolumab for SMARCA4‐deficient non‐small cell lung carcinoma with a high tumor mutation burden: A case report (2019)
  • Author(s): Naito Tomoyuki、Umemura Shigeki、Nakamura Hiroshi、Zenke Yoshitaka、Udagawa Hibiki、Kirita Keisuke、Matsumoto Shingo、Yoh Kiyotaka、Niho Seiji、Motoi Noriko、Aokage Keijyu、Tsuboi Masahiro、Ishii Genichiro、Goto Koichi
  • Journal Title: Thoracic Cancer Volume: 10 Issue: 5 Pages: 1285-1288
  • DOI: 10.1111/1759-7714.13070
  • Peer Reviewed / Open Access
• [Journal Article] A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non?Small Cell Lung Carcinoma (2019)
  • Author(s): Naito Tomoyuki、Udagawa Hibiki、Sato Jun、Horinouchi Hidehito、Murakami Shuji、Goto Yasushi、Kanda Shintaro、Fujiwara Yutaka、Yamamoto Noboru、Zenke Yoshitaka、Kirita Keisuke、Matsumoto Shingo、Yoh Kiyotaka、Niho Seiji、Motoi Noriko、Ohe Yuichiro、Ishii Genichiro、Goto Koichi
  • Journal Title: Journal of Thoracic Oncology Volume: 14 Issue: 10 Pages: 1818-1827
  • DOI: 10.1016/j.jtho.2019.06.019
  • Peer Reviewed
• [Journal Article] Immunocytochemistry for predictive biomarker testing in lung cancer cytology (2019)
  • Author(s): Jain Deepali、Nambirajan Aruna、Borczuk Alain、Chen Gang、Minami Yuko、Moreira Andre L.、Motoi Noriko、Papotti Mauro、Rekhtman Natasha、Russell Prudence A.、Savic Prince Spasenija、Yatabe Yasushi、Bubendorf Lukas、the IASLC Pathology Committee
  • Journal Title: Cancer Cytopathology Volume: 127 Issue: 5 Pages: 325-339
  • DOI: 10.1002/cncy.22137
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study (2019)
  • Author(s): Sunami Kuniko、Ichikawa Hitoshi、Kubo Takashi、Kato Mamoru、Fujiwara Yutaka、Shimomura Akihiko、Koyama Takafumi、Kakishima Hiroki、Kitami Mayuko、Matsushita Hiromichi、Furukawa Eisaku、Narushima Daichi、Nagai Momoko、Taniguchi Hirokazu、Motoi Noriko、、Kohno Takashi et al.
  • Journal Title: Cancer Science Volume: 110 Issue: 4 Pages: 1480-1490
  • DOI: 10.1111/cas.13969
  • Peer Reviewed / Open Access
• [Journal Article] Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer (2018)
  • Author(s): Sekine Katsutoshi、Kanda Shintaro、Goto Yasushi、Horinouchi Hidehito、Fujiwara Yutaka、Yamamoto Noboru、Motoi Noriko、Ohe Yuichiro
  • Journal Title: Lung Cancer Volume: 124 Pages: 179-188
  • DOI: 10.1016/j.lungcan.2018.08.012
  • Peer Reviewed / Open Access
• [Presentation] 進行/再発肺大細胞神経内分泌癌における,Pd-1阻害剤の効果と腫瘍免疫微小環境との関連についての検討 (2021)
  • Author(s): 白澤 昌之, 吉田 達哉, 関根 克敏, 神田 慎太郎, 松元 祐司, 増田 健, 新野 祐樹, 大熊 裕介, 後藤 悌, 堀之内 秀仁, 山本 昇, 渡辺 俊一, 元井 紀子, 大江 裕一郎
  • Organizer: 第62回日本肺癌学会学術集会
• [Presentation] IV期原発性肺癌に対してPembrolizumab治療後にsalvage手術を施行した1例 (2021)
  • Author(s): 藤川 遼, 吉田 幸弘, 四倉 正也, 中川 加寿夫, 渡辺 俊一, 加島 淳平, 元井 紀子, 谷田部 恭, 新野 祐樹, 大江 裕一郎, 土田 敬明, 渡辺 裕一, 楠本 昌彦.
  • Organizer: 第62回日本肺癌学会学術集会
• [Presentation] 進行期NSCLCにおける悪液質の病態およびPembrolizumab治療効果の関係 (2021)
  • Author(s): 徐 仁美, 吉田 達哉, 柳下 薫寛, 堀之内 秀仁, 松元 祐司, 新野 祐樹, 大熊 裕介, 後藤 悌, 山本 昇, 元井 紀子, 大江 裕一郎
  • Organizer: 第62回日本肺癌学会学術集会
• [Presentation] Predictive Efficacy of Morphological Biomarkers Based on Digital Pathology for ICI Therapy of Non-Small Cell Lung Cancer (2020)
  • Author(s): ?サソMotoi N, Yoshida H, Kiyuna T, Saiga H, Horinouchi H, Yoshida T, Kohno T, Watanabe S-i, Ohe Y, Ochiai A
  • Organizer: 2020 World Conference on Lung Cancer (WCLC)
  • Int'l Joint Research
• [Presentation] Impact of SWI/SNF complex mutations in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors: Immuno-oncology biomarker study in LC-SCRUM-Japan (LC-SCRUM-IBIS) (2020)
  • Author(s): Yoh K, Matsumoto S, Furuya N, Nishino K, Miyamoto S, Oizumi S, Okamoto N, Itani H, Kuyama S, Nakamura A, Hayashi Y, Motoi N, Ishii G, Goto K
  • Organizer: 2020 ASCO
  • Int'l Joint Research
• [Presentation] Clinical Genomic Test on Cytology: Current Status and Future Perspective in Japan (JSCC Working Group on Cytological Roles in Genome Medicine Era) (2019)
  • Author(s): Motoi N, Yutaka Hatanaka, Shinji Hamakawa, Akihiko Kawahara, Nagatomo T, Kuwata T, Oda Y, Okamoto A, Maeda I, Sato Y, Morii E
  • Organizer: 20th International Congress of Cytology
  • Int'l Joint Research / Invited
• [Presentation] Exploring morphological biomarkers for a better patients’ selection to the immune therapy of non-small cell lung cancer (2019)
  • Author(s): Motoi N, Yoshida H, Kiyuna T, Saiga H, Yamashita Y, Kohno T, Watanabe S-i, Ohe Y, Ochiai A
  • Organizer: 2019 World Conference on Lung Cancer (WCLC)
  • Int'l Joint Research
• [Presentation] Influences of Sampling Method to Morphological Feature Measurement of Lung Cancer Cell (2019)
  • Author(s): Kiyuna T, Motoi N, Yoshida H, Watanabe S-i, Ohe Y, Ochiai A
  • Organizer: 2019 World Conference on Lung Cancer (WCLC)
  • Int'l Joint Research
• [Presentation] 肺癌病理バイオマーカー診断の今：個別検査とパネル検査 (2019)
  • Author(s): 元井紀子
  • Organizer: 第108回 日本病理学会総会
  • Invited
• [Presentation] 細胞診検体を用いたがんゲノム検査：日本での現状と推進への課題 (2019)
  • Author(s): 元井紀子
  • Organizer: 第58回日本臨床細胞学会秋期大会
  • Invited
• [Presentation] Exploring Morphological Biomarker for Predicting Responsiveness to the Immune Checkpoint Inhibitor Therapy using Whole-Slide Digital Images of Non-Small Cell Lung Cancer (2019)
  • Author(s): Noriko Motoi Hiroshi Yoshida Tomoharu Kiyuna Hiroyasu Saiga Yoshiko Yamashita Takashi Kohno Yuichiro Ohe Atsushi Ochiai
  • Organizer: The 108th USCAP Annual Meeting
  • Int'l Joint Research
• [Presentation] Digital Image-based Morphological Feature as a Useful Predictive Biomarker for Immune Checkpoint Inhibitor Therapy of Non-Small Cell Lung Cancer (2018)
  • Author(s): Motoi, Noriko Yoshida, Hiroshi Kiyuna, Tomoharu Saiga, Hiroyasu Yamashita, Yoshiko Sekine, Katsutoshi Honda, Takayuki Kanda, Shintaro Horinouchi, Hidehito Kohno, Takashi Ohe, Yuichiro Ochiai, Atsushi
  • Organizer: The 6th JCA-AACR Special Joint Conference
  • Int'l Joint Research